Toripalimab

特瑞普利单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameToripalimab
Drug Alias Name特瑞普利单抗注射液TreprilumabTriplegmabTriplizumabtoripalimab-tpzi +[22] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsRejection of organ transplantationMetastatic breast cancerOral Squamous Cell Carcinoma +[42] 
Global Approved IndicationsNasopharyngeal CarcinomaEsophageal Squamous Cell CarcinomaMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryMainland China
Original Approved Date2018/12/17
Country/TerritoryUnited StatesUkraineSingapore +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Union Biopharm Biosciences Co LtdShanghai Junshi Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Jiatan Pharmaceutical Technology Co LtdTopalliance Biosciences IncHenan Provincial Cancer Hospital +[20] 
Inactive CompaniesPeking UniversityBeijing Friendship Hospital Co LtdZhejiang University
Active IndicationsOral Squamous Cell CarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[33] 
Inactive IndicationsRejection of organ transplantationMetastatic breast cancerNasopharyngeal Diseases +[9] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG